No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
APLS Apellis Pharmaceuticals
- 33.210
- +0.070+0.21%
Close Dec 20 16:00 ET
- 33.210
- 0.0000.00%
Post 16:15 ET
4.13BMarket Cap-16.36P/E (TTM)
34.270High32.890Low3.73MVolume33.160Open33.140Pre Close124.43MTurnover4.43%Turnover RatioLossP/E (Static)124.39MShares73.80052wk High17.42P/B2.80BFloat Cap24.34052wk Low--Dividend TTM84.36MShs Float94.750Historical High--Div YieldTTM4.16%Amplitude11.450Historical Low33.330Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
Goldman Sachs Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to a Hold
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock the Full List
